AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
- Posted on September 29, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
AbbVie ABBV announced that the FDA has approved tavapadon as a once-daily oral treatment for Parkinson’s disease (PD). The drug, which will be marketed under the brand name Juvmo, will be commercially launched next month. Per the company, this approval marks the first ‘dopaminergic breakthrough’ for PD in decades. Juvmo can be used alone or in combination with levodopa, the current standard of care for PD symptoms. This may be particularly...
